Nanobiotix Reports Strong Phase 2 NSCLC Data & Accelerates Pivotal Phase 3 HNSCC Trial
NBTX has more than doubled off its 52-week low of $3.64.
Summary
Nanobiotix announced promising Part 1 data from its Phase 2 CONVERGE trial in NSCLC, showing a 57.1% complete response rate, and confirmed an accelerated timeline for the pivotal Phase 3 NANORAY-312 trial in head and neck cancer.
Key Events · Product Development and Regulatory · NBTX
-
Promising Phase 2 NSCLC Data
Part 1 data from the CONVERGE trial showed an 85.7% objective response rate (ORR) and a 57.1% complete response rate (CRR) in 7 patients with unresectable Stage 3 NSCLC, an improvement over previously reported initial data.
-
Pivotal Phase 3 Trial Accelerated
The NANORAY-312 trial for head and neck cancer will eliminate its interim analysis and conduct the final analysis sooner with fewer events, aiming to accelerate the global registration pathway for JNJ-1900 (NBTXR3).
-
Curadigm Platform Progress
New preclinical data demonstrated the Nanoprimer technology's potential to enhance LNP-delivered immunotherapies by improving systemic bioavailability and reducing liver toxicity.
Analysis · NBTX · Life Sciences
This filing provides significant positive updates on two key clinical programs. The improved complete response rate in the CONVERGE trial, while preliminary, suggests strong efficacy for JNJ-1900 (NBTXR3) in non-small cell lung cancer. Simultaneously, accelerating the final analysis of the pivotal NANORAY-312 trial for head and neck cancer could bring the product to market sooner, potentially boosting future revenue and reducing development risk. These updates reinforce the company's clinical progress and partnership with Johnson & Johnson.
At the time of this filing, NBTX was trading at $40.01 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $2.2B. The 52-week trading range was $3.64 to $57.14. This filing was assessed with positive market sentiment and an importance score of 9 out of 10.